in

Weight Loss Drugs Ozempic and Wegovy Linked to Blindness Risk

Semaglutide-based weight loss drugs such as Ozempic and Wegovy are under scrutiny after a study by Massachusetts-based researchers flagged a potential link to a rare form of blindness. The researchers examined data from over 16,000 patients with type 2 diabetes or who were overweight or obese. They found that those using semaglutide-containing drugs faced a higher risk of developing nonarteritic anterior ischemic optic neuropathy (NAION).

Although the study did not definitively prove causation, it raised concerns about the safety of these drugs. With Ozempic catering to diabetes patients and Wegovy targeting weight loss, the higher semaglutide content in the latter could pose greater risks. The FDA has also issued warnings about counterfeit Ozempic being sold online, adding to the uncertainties surrounding these medications.

NAION, characterized by a sudden loss of vision in one eye due to decreased blood flow to the optic nerve, is a rare condition affecting a small portion of the population annually. The researchers from Harvard and Brigham and Women’s Hospital have called for further investigation into the potential risks associated with semaglutide use.

As conservative Americans navigate healthcare choices, news like this serves as a reminder to approach fad treatments with caution. While weight loss drugs may promise quick results, the potential for severe side effects like blindness cannot be ignored. It’s crucial for individuals to weigh the risks and benefits carefully before opting for pharmaceutical solutions to health concerns.

Written by Staff Reports

Leave a Reply

Your email address will not be published. Required fields are marked *

Trump Challenges Biden to Unscripted Debate, Questions Competence

Federal Judge Blocks Biden Plan to Redefine Sex in Title IX